Lodz

• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Ended recruitment
  2023-507329-40-00 6 2017-09-28 1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination wi … Ended recruitment
  2023-509354-58-00 5 2017-07-14 Mantle Cell Lymphoma
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisi … Ended recruitment
  2023-509359-15-00 5 2017-03-08 Relapsed or Refractory Chronic Lymphocytic Leukemia
• A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab ( … Ended recruitment
  2023-509353-31-00 2 2016-09-05 Mantle Cell Lymphoma
• An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended recruitment
  2023-505246-26-00 5 2016-01-27 High- or very-high risk, localized or locally advanced prostate cancer
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended recruitment
  2023-509425-53-00 5 2015-11-09 Atopic Dermatitis
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl … Ended recruitment
  2023-506524-82-00 5 2015-10-21 Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
• A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High R … Ended recruitment
  2023-509347-27-00 5 2015-09-30 High Risk Chronic Lymphocytic Leukaemia
• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study Halted
  2024-518951-52-00 4 2025-11-12 Worsening Heart Failure
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate- … Ended
  2024-512497-10-00 5 2025-09-16 Moderate to Severe Plaque Psoriasis
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• clinical trial evaluating the efficacy of nintedanib with tocilizumab compared to standard treatment in patients with systemic sclerosis and … Ended
  2024-517005-85-00 5 2025-07-01 systemic sclerosis with interstitial lung disease (ILD) in the course
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended
  2024-513435-24-01 4 2025-06-03 Neuropathic Pain; Distal Sensory Polyneuropathy
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KR … Ended
  2024-516699-14-00 7 2025-04-23 Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenoca
• A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder … Ended
  2024-511549-20-00 4 2025-04-22 Dermatitis atopic
• Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended
  2024-515615-22-00 4 2025-04-02 Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection

Showing 649–672 of 898 trials